Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Orion Pharma's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -8.73%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Orion Pharma's 1-Year ROIIC % or its related term are showing as below:
DHA:ORIONPHARM's 1-Year ROIIC % is ranked worse than 70.77% of 414
companies
in the Utilities - Independent Power Producers industry
Industry Median: 0.495
vs DHA:ORIONPHARM: -8.73
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Orion Pharma 1-Year ROIIC % Related Terms
Orion Pharma 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Orion Pharma's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: 1-Year ROIIC % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma 1-Year ROIIC % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's 1-Year ROIIC % falls into.
Orion Pharma's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -125.569 (Mar. 2026) - 89.1354 (Mar. 2025) )
/
( 49254.017 (Mar. 2026) - 46795.778 (Mar. 2025) )
=
-214.7044
/
2458.239
=
-8.73%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Orion Pharma (DHA:ORIONPHARM) has a 1-Year ROIIC % of -8.73 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #293 out of 414 companies in the Utilities - Independent Power Producers industry, placing it in the top 70.8%.
Is Orion Pharma's 1-Year ROIIC % too high?
Orion Pharma's current 1-Year ROIIC % is -8.73. Based on the distribution chart, Orion Pharma ranks #293 out of 414 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's 1-Year ROIIC % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #293 out of 414 companies for 1-Year ROIIC %. This places Orion Pharma in the lower half of its industry. The industry median 1-Year ROIIC % is 0.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for an Utilities - Independent Power Producers company?
The median 1-Year ROIIC % among Utilities - Independent Power Producers companies is 0.50, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median 1-Year ROIIC % is 0.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current 1-Year ROIIC % is -8.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.17, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current 1-Year ROIIC % is -8.73. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current 1-Year ROIIC % is -8.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.17.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
1-Year ROIIC %: -8.73
GF Value™: BDT20.17 vs. price of BDT30.10 (49.2% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score
Get the complete analysis for DHA:ORIONPHARM
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
